TW202334136A - PI3Kα抑制劑及其製造與使用方法 - Google Patents
PI3Kα抑制劑及其製造與使用方法 Download PDFInfo
- Publication number
- TW202334136A TW202334136A TW111141786A TW111141786A TW202334136A TW 202334136 A TW202334136 A TW 202334136A TW 111141786 A TW111141786 A TW 111141786A TW 111141786 A TW111141786 A TW 111141786A TW 202334136 A TW202334136 A TW 202334136A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- iii
- formula
- solid
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| US63/263,474 | 2021-11-03 | ||
| CN2021128533 | 2021-11-03 | ||
| WOPCT/CN2021/128533 | 2021-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202334136A true TW202334136A (zh) | 2023-09-01 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111141786A TW202334136A (zh) | 2021-11-03 | 2022-11-02 | PI3Kα抑制劑及其製造與使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260125374A1 (enExample) |
| EP (1) | EP4426314A4 (enExample) |
| JP (1) | JP2024540303A (enExample) |
| KR (1) | KR20240112283A (enExample) |
| CN (1) | CN118401245A (enExample) |
| AU (1) | AU2022381187A1 (enExample) |
| CA (1) | CA3236861A1 (enExample) |
| CL (1) | CL2024001364A1 (enExample) |
| IL (1) | IL312466A (enExample) |
| MX (1) | MX2024005429A (enExample) |
| PE (1) | PE20250676A1 (enExample) |
| TW (1) | TW202334136A (enExample) |
| WO (1) | WO2023081757A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| JP6472803B2 (ja) * | 2013-09-05 | 2019-02-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾロピリジン化合物、その組成物及び使用方法 |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3931188B1 (en) * | 2019-02-26 | 2023-08-30 | Boehringer Ingelheim International GmbH | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| AU2021263914B2 (en) * | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 US US18/706,511 patent/US20260125374A1/en active Pending
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024001364A1 (es) | 2024-10-25 |
| KR20240112283A (ko) | 2024-07-18 |
| EP4426314A1 (en) | 2024-09-11 |
| IL312466A (en) | 2024-06-01 |
| MX2024005429A (es) | 2024-05-21 |
| CN118401245A (zh) | 2024-07-26 |
| JP2024540303A (ja) | 2024-10-31 |
| EP4426314A4 (en) | 2025-10-01 |
| US20260125374A1 (en) | 2026-05-07 |
| PE20250676A1 (es) | 2025-03-04 |
| CA3236861A1 (en) | 2023-05-11 |
| AU2022381187A1 (en) | 2024-05-16 |
| WO2023081757A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3224985C (en) | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | |
| US20260125374A1 (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| WO2023060262A1 (en) | Pi3k-alpha inhibitors and methods of use thereof | |
| JP6980649B2 (ja) | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 | |
| CN116261562A (zh) | PI3K-α抑制剂和其使用方法 | |
| TW202233625A (zh) | Ｆｇｆｒ抑制劑及其製造及使用方法 | |
| TW200806664A (en) | Azaindoles useful as inhibitors of janus kinases | |
| CA2879400A1 (en) | Deuterated ibrutinib | |
| CN118201896A (zh) | PI3K-α抑制剂和其使用方法 | |
| WO2019189732A1 (ja) | 光学活性な架橋型環状２級アミン誘導体 | |
| CN119486992A (zh) | PI3Kα抑制剂及其使用方法 | |
| JP2024051160A (ja) | ピリミジン誘導体の医薬塩及び障害の処置方法 | |
| JP2021500366A (ja) | 置換されているイミダゾピリジンアミド類及びそれらの使用 | |
| EP4426286A1 (en) | Bifunctional pi3k-alpha inhibitors and uses thereof | |
| JP7781327B2 (ja) | 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 | |
| JP2022521491A (ja) | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 | |
| EP3101020B1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| EP3730492A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof | |
| TW202527954A (zh) | PI3Kα抑制劑及其製造與使用方法 | |
| CN120676939A (zh) | Pi3k抑制剂及其制备和使用方法 | |
| CN118251217A (zh) | PI3Kα抑制剂及其使用方法 | |
| EA051309B1 (ru) | Ингибиторы pi3k-альфа и способы их получения и использования | |
| WO2026044398A1 (en) | Salts of 5-chloro-2-fluoro-n-(2-fluoro-4-(3-methyl-4-[(1-methylpiperidin-4-yl)oxy]-1h-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)benzene sulfonamide and crystalline forms thereof | |
| CN118126051A (zh) | 突变体braf降解剂的多晶型物及其制备方法 | |
| NZ743251A (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |